D.E. Shaw is Going to Trial Over the Sale of a Litigation Finance Portfolio Company, Shining a Light on a Side-Pocket Deal at the Secretive Hedge Fund...
Keep Reading →
September 10 - Hedge Funds, Insider Trading - Comments
The biotech industry is regaining ground it lost in 2016 at full speed. The sector was very hot until around mid-2015, with the iShares Nasdaq Biotechnology...
Keep Reading →
July 19 - Hedge Funds, News - Comments
Rovio Entertainment Oyj (OTCMKTS:ROVVF) (MarketWatch) Shares in Rovio Entertainment Ltd. (ROVIO.HE) sank further Friday after it warned that competition...
Keep Reading →
March 2 - Market Movers, News - Comments
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) (Benzinga) Tetraphase Pharmaceuticals Inc’s Ignite3 trial evaluating the company’s lead drug...
Keep Reading →
February 14 - Market Movers, News - Comments
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the...
Keep Reading →
March 21 - News, Stock Analysis - Comments
Although the broader markets are relatively calm, five stocks, Nektar Therapeutics (NASDAQ:NKTR), Advanced Micro Devices, Inc. (NASDAQ:AMD), Esperion...
Keep Reading →
March 20 - News - Comments
According to research firm TrimTabs, the dollar volume of insider buying from early-October through the end of last week stood at about $110 million,...
Keep Reading →
October 26 - Insider Trading, News - Comments
It’s been another busy start to the week in biotech, with a number of companies moving double digit percentage points on various fundamental releases...
Keep Reading →
October 20 - Market Movers, News - Comments
Stocks indexes have jumped higher today amid better-than-expected earnings from Netflix, Inc. (NASDAQ:NFLX) and Goldman Sachs Group Inc (NYSE:GS), and...
Keep Reading →
October 18 - Market Movers, News - Comments
Cheyne Capital is one of the few non-U.S firms that we track in our database. Managed by its founders, Jonathan Lourie and Stuart Fiertz, Cheyne employs...
Keep Reading →
October 21 - Hedge Fund Analysis, Hedge Funds, News - Comments
Stan Druckenmiller’s Duquesne Family Office LLC, previously Duquesne Capital, has filed its 13F for the reporting period of March 31. Druckenmiller...
Keep Reading →
May 28 - Hedge Funds, News - Comments
Here’s your one-question pop quiz of the day. Does MannKind Corporation (NASDAQ:MNKD) deserve a market cap of: $1.4 billion $1.7 billion $2.2 billion...
Keep Reading →
September 17 - News - Comments
Is Nektar Therapeutics (NASDAQ:NKTR) a good investment? Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment...
Keep Reading →
September 17 - News - Comments
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age. Although there are In excess of 8,000 hedge funds...
Keep Reading →
September 11 - News - Comments
Is it smart to be bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT)? If you were to ask many of your fellow readers, hedge funds are seen as overrated...
Keep Reading →
August 30 - News - Comments
Nektar Therapeutics (NASDAQ:NKTR) announced data last week that could become a breakthrough in the largest healthcare market in the U.S. – but how much...
Keep Reading →
June 26 - News - Comments
While the market jittered this week over what the Federal Reserve will do next, some stocks didn’t flinch. The fortunate investors were those who...
Keep Reading →
June 24 - News - Comments
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds’ portfolio at the end of March. NKTR has experienced a decrease in support from the world...
Keep Reading →
June 12 - News - Comments
ImmunoGen, Inc. (NASDAQ:IMGN) investors should pay attention to a decrease in hedge fund interest recently. At the moment, there are dozens of methods...
Keep Reading →
April 19 - News - Comments
Synageva BioPharma Corp (NASDAQ:GEVA) has experienced an increase in hedge fund sentiment in recent months. At the moment, there are dozens of metrics...
Keep Reading →
April 19 - News - Comments
Earnings season is getting ready to rev into high gear, but earnings are unlikely to be the talk of the sector in the days to come, with three big Food...
Keep Reading →
April 14 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I’d be unable to keep up on...
Keep Reading →
April 10 - News - Comments
Between April and June of this year, Orbimed Advisors sold 18% of its shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX), finishing the second quarter...
Keep Reading →
October 1 - Hedge Funds - Comments
